Abstract:Although liver transplantation is the most effective long-term treatment for hepatocellular carcinoma (HCC), the recurrence of HCC remains an issue. Current research examining recurrence after liver transplantation primarily focuses on patients' clinical characteristics. There is no consensus regarding the factors that may relate to predict the survival time and recurrence rates for patients with hepatitis B virus (HBV)-associated HCC transplantation using clinicopathological analysis.One hundred and three patients with HCC were enrolled in the study. All data were collected from the China Liver Transplant Registry. The independent variables were as follows: age, gender, etiology, preoperative alpha-fetoprotein (AFP) levels, body mass index (BMI), Model for End-stage Liver Disease (MELD) and Child-Pugh scores, primary tumor, regional nodes, metastasis (TNM) classification, number of tumors, the size for the largest tumor, multifocality, portal vein tumor thrombosis and histological differentiation, and prognostic staging score criteria (Milan criteria). All of the patients had previously undergone liver transplantation. Univariate and multivariate analysis were used to determine the factors related to the survival time and recurrence.After a median follow-up period of 41.05±28.90 months, the 5-year overall survival rate was 46.60%, and the 5-year recurrence rate was 45.63%. Forty-seven patients (45.63%) died due to HCC recurrence during the follow-up period. Patients within Milan criteria exhibited excellent post-transplantation survival times. Univariate analysis suggested that patients with poor tumor differentiation, AFP≥400ng/ml, portal vein tumor thrombosis, and TNM staging of I+II had significantly predicted shorter survival times and higher recurrence than patients displaying good or moderate tumor differentiation, AFP<400ng/ml, no portal vein thrombosis and TNM staging of III+IV for HBV-associated HCC. However, multivariate analysis revealed that poor tumor differentiation and high serum AFP were associated with a shorter survival time. Moreover, poor tumor differentiation suggested high recurrence. In addition, patients' survival time with AFP<400ng/ml was longer than that of patients with AFP≥400ng/ml even in patients with HCC beyond Milan criteria.Tumor biological characteristics especially histological differentiation and serum AFP level should be considered before performing liver transplantation (LT) for patients with HBV-associated HCC. Furthermore, the AFP level and histological differentiation provide a new method for assessing HCC patient survival time after LT. Histological differentiation independently predicted post-transplantation survival time and recurrence rate for patients with HBV-associated HCC.

Human leukocyte antigen-G and prognosis of liver transplantation in patients with hepatocellular carcinoma

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Impact of Human Leukocyte Antigen Matching on Hepatitis B Virus Recurrence after Liver Transplantation.

Clonal Origin of Hepatocellular Carcinoma and Recurrence after Liver Transplantation

[Liver Transplantation for Hepatocellular Carcinoma: Prognostic Analysis of 89 Cases].

Expression of HLA-G in Patients with Hepatocellular Carcinoma.

High CXCL1 Level Correlates with Poor Prognosis of HBV-associated Hepatocellular Carcinoma after Liver Transplantation

The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma

Prognostic Value of HLA Class I in Patients with Hepatocellular Carcinoma

Use of Cancer-Testis Antigen Mrna As Specific Markers to Evaluate the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation

BAG3 and HIF-1 Α Coexpression Detected by Immunohistochemistry Correlated with Prognosis in Hepatocellular Carcinoma after Liver Transplantation.

Genetic Variations in Plasma Circulating DNA of HBV-Related Hepatocellular Carcinoma Patients Predict Recurrence after Liver Transplantation

[Influence of Tumor Characteristics on the Outcome of Liver Transplantation among Patients with Hepatocellular Carcinoma].

Analysis of the Risk Factors Influencing the Prognosis of Orthotopic Liver Transplantation for Hepatocellular Carcinoma and Summary of Relevant Clinical Experience

Correlation Between Recurrence of Primary Hepatocellular Carcinoma after Liver Transplantation and Expression of CK19 and GPC3

Analysis of survival and prognostic factors of liver transplantation for hepatocellular carcinoma

Role of Leukemia Inhibitory Factor in Predicting Recurrence of Hepatocellular Carcinoma in Recipients Undergoing Liver Transplantation

Expression of ANLN in HCC and predictive value for long-term survival of patients after liver transplantation

Histological differentiation predicts post-liver transplantation survival time.

Long-term Survival and Risk Factors of Prognosis after Liver Transplantation for Malignant Liver Tumors